Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nonmalignant Diseases Clear all
Not listed No phase listed Observational
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
0 Years to 24 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Precancerous/Nonmalignant Condition, Prostate Cancer
Interventions
calcitriol, observation
Dietary Supplement · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
5
States / cities
East Brunswick, New Jersey • Morristown, New Jersey • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced May 21, 2026, 6:54 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immune Deficiency, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi Anemia, Thalassemia, Sickle Cell Disease
Interventions
Thiotepa
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728), placebo
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Mobile, Alabama • Sun City, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Non-Neoplastic Hematologic and Lymphocytic Disorder
Interventions
Allogeneic Bone Marrow Transplantation, Anti-Thymocyte Globulin, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Methotrexate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total-Body Irradiation, Treosulfan, Umbilical Cord Blood Transplantation
Procedure · Biological · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 49 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Portland, Oregon • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced May 21, 2026, 6:54 PM EDT
Not listed Phase 3 Interventional
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hurler Syndrome, Fanconi Anemia, Glanzmann Thrombasthenia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency, Shwachman-Diamond Syndrome, Diamond-Blackfan Anemia, Dyskeratosis-congenita, Chediak-Higashi Syndrome, Severe Aplastic Anemia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Sickle Cell Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced May 21, 2026, 6:54 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Cerebellar Neoplasm
Interventions
Medoc Advanced Medical Systems PATHWAY Model ATS, Cold water bath, MRI scanner, Questionnaires
Device · Procedure · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
6 Years to 38 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, High Risk Hematologic Disorders, Cerebral Adrenoleukodystrophy, Inherited Metabolic Disorders
Interventions
Blood and Marrow Transplant
Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 25 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced May 21, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Interventions
Tetanus
Biological
Lead sponsor
Robert Krance
Other
Eligibility
3 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Bone marrow transplantation, Mesenchymal Stromal Cells
Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Nonmalignant Neoplasm, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
anti-thymocyte globulin, busulfan, carboplatin, cyclophosphamide, etoposide, fludarabine phosphate, melphalan, thiotepa, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
4 Years to 70 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced May 21, 2026, 6:54 PM EDT
Not listed Not applicable Interventional
View directory record Official record
Conditions
Wounds, Chronic Wounds, Nonmalignant Condition
Interventions
DermACELL®, Integra®
Device
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced May 21, 2026, 6:54 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
chemotherapy, dapsone, medical chart review, assessment of therapy complications
Drug · Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
Up to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis, Uterine Prolapse, Precancerous/Nonmalignant Condition, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
Robotic Assisted-Surgery (RAS) Hysterectomy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Jacksonville, Florida • Tampa, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
Interventions
Thiotepa, Treosulfan, Fludarabine Phosphate, Rabbit Anti-Thymocyte Globulin, Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Biopsy, Bone Marrow Aspiration, Magnetic Resonance Imaging, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 6:54 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Precancerous/Nonmalignant Condition
Interventions
PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
Interventions
Thiotepa--single daily dose, Thiotepa--escalated dose
Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Months to 39 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclophosphamide, TBI
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced May 21, 2026, 6:54 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Malignant Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Lapine T-Lymphocyte Immune Globulin, Total-Body Irradiation, Hematopoietic Cell Transplantation, Mycophenolate Mofetil, Sirolimus, Bone Marrow Aspiration, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced May 21, 2026, 6:54 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
monoclonal antibody A27.15, monoclonal antibody E2.3
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced May 21, 2026, 6:54 PM EDT